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 Abstract 
Catastrophic Antiphospholipid syndrome (CAPS) is a very severe variant of the classic APS, 
characterised by clinical evidence of multiple organ involvement developing over a very short 
period of time,  histopathological evidence of multiple small vessel occlusions, and  laboratory 
confirmation of the presence of antiphospholipid antibodies (aPL), usually in high titre. Although 
patients with catastrophic APS represent less than 1% of all patients with APS, this is usually a 
life-threatening condition.  
In this article we aimed to review the state-of-the art about current knowledge in pathogenesis, 
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 Introduction 
Catastrophic Antiphospholipid syndrome (CAPS) was first described by Asherson in 1992 [1]. It 
characterised  by multiple vascular occlusive events, presenting over a short period of time, in 
patients with aPL positive. It is an uncommon presentation that occurs in <1% of APS patients, 
often after a triggering factor such as anticoagulation withdrawal, surgery, minor surgical 
procedures, or infections.  Mortality rate is around 50% and treatment includes corticosteroids, 
anticoagulation, intravenous immunoglobulin and plasma exchange [2]. 
Pathogenesis 
The etiopathogenesis of catastrophic APS remains incompletely understood. Several mechanisms 
have been proposed such as molecular mimicry,  infections,  activation of endothelium in the 
microvasculature and microvascular occlusions [3].   Kitchens et al [4]  have suggested that the 
vascular occlusions are themselves responsible for the ongoing thrombosis. Clots continue to 
generate thrombin, fibrinolysis is impaired by an increase in plasminogen activator inhibitor type-
1 (PAI-1), and there is consumption of the natural anticoagulant proteins such as protein C and 
antithrombin. These multiple small-vessel occlusions cause extensive tissue necrosis which 
results in a systemic inflammatory response syndrome (SIRS), with excessive cytokine release 
from affected and necrotic tissues [5] . Proinflammatory cytokines, several products of the 
activated complement system (e.g. C3b, iC3b and C5a) and aPL themselves have each been 
demonstrated to activate endothelial cells, provide a stimulatory signal and upregulate adhesion 
molecules and tissue factor. These molecules can also act on leukocytes and platelets to increase 
their adhesion to vascular endothelium and to promote microthrombosis and the local release of 
toxic mediators, including proteases and oxygen-derived free radicals. The interaction between all 
these cells in the presence of aPL leads to the diffuse microvasculopathy that characterises CAPS 
and leads to multiorgan failure [3, 5, 6].  
 
Clinical manifestations 
The most common known trigger for CAPS is infection.  Other less common causes are 
anticoagulation withdrawal or low international normalized ratio (INR), medications (e.g oral 
contraceptive), obstetric complications, neoplasia, systemic lupus erythematosus (SLE) flares, 
trauma, and surgery.  Nevertheless, in almost half of the cases, no obvious precipitating factors 
have been identified and CAPS can often occur in patients without any previous thrombotic 
history [2].  
The clinical manifestations of CAPS depend on the organs that are affected, by the thrombotic 
events and the extent of the thrombosis, together with manifestations of the SIRS. 
In contrast to classic APS, single venous or arterial medium to large blood vessel occlusions are 
uncommon in patients with catastrophic APS. Multiple organ dysfunction and failure, as a 
consequence of thrombotic microangiopathy, are responsible for the majority of the clinical 
features; however, large venous or arterial thrombosis can also occur in about one fifth of 
patients. In a review of 280 patients with CAPS [2] from the website based international CAPS 
registry, Cervera et al. reported that the first clinical manifestation at the time of the catastrophic 
episode was a pulmonary complication in 24% of the cases, a neurologic feature in 18% and a 
renal feature in 18%. Although the initial presentation of CAPS may involve a single organ, in a 
very short period of time, typically days to weeks, patients develop clinical evidence of multiple 
organ thrombosis and dysfunction leading to organ failure that requires intensive care unit 
admission.  In the same cohort of CAPS patients [2] during the catastrophic episode, 
intraabdominal involvement was identified in the majority of patients, mainly consists of renal 
(71%), hepatic (33%), gastrointestinal (25%), splenic (19%), adrenal (13%), and pancreatic (8%) 
manifestations. Intrathoracic involvement was also common and included pulmonary 
complications (64%), mainly acute respiratory distress syndrome (ARDS) and pulmonary 
embolism, but occasionally intraalveolar hemorrhage, as well as cardiac manifestations (51%), 
mainly cardiac failure and myocardial infarction or valve lesions. Cerebrovascular complications 
were also frequently present (62%), mainly consists of encephalopathy and cerebrovascular 
accidents, but occasionally seizures, headache or silent brain infarcts. Skin manifestations were 
also frequent (50%) with  livedo reticularis, leg ulcers, necrotic lesions, digital gangrene, purpura, 
splinter haemorrhages, and multiple ecchymosis. Deep venous thrombosis (23%) and peripheral 
arterial occlusive disease (11%) were less frequently detected. Other lesions occasionally 
encountered were retinal involvement (7%), mononeuritis multiplex (5%) and bone marrow 
necrosis (4%) [2].  
 
APS-related laboratory findings 
The most common APS related-laboratoy findings are thrombocytopenia,  hemolytic anemia 
(often accompanied of schistocytes as in thrombotic microangiopathic hemolytic anemia), and 
disseminated intravascular coagulation (DIC). The presence of aPL, namely anticardiolipin (aCL), 
anti-β2-glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) is mandatory for the diagnosis. 
aPL are usually detected in high titre in CAPS patients. The role of other aPL, such as anti-
phosphatidylserine/prothrombin or anti-prothrombin in solid phase  has been  reported [7], but its 
role is still controversial. 
  
Diagnosis 
The diagnosis of CAPS can be challenging because of the acute onset of thrombosis at multiple 
levels with simultaneous dysfunction of different organs. The survival of the patients very much 
depends on an early diagnosis and treatment.  
Preliminary CAPS classification criteria (Table 1) was proposed and agreed in Taormina, (Sicily) 
during the 10
th
 International Congress on aPL.  Although these criteria are accepted for 
classification purposes, they might be a guide to a more consistent approach to the diagnosis [8].  
An update of the diagnostic algorithm  for CAPS was recently proposed [9] and discussed in 
‘Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS 
Manifestations’  developed on the occasion of the 13th International Congress on 
Antiphospholipid, held in Galveston (Texas) in 2011[10]. This approach represents a step forward 
in diagnosis of CAPS but it needs to be validated versus other thrombotic microangiopathy.   
To make the diagnosis of CAPS, there should be clinical evidence of multiple organ involvement 
developed over a short period of time, histopathologic evidence of multiple small-vessel 
occlusions and laboratory confirmation of the presence of aPL, usually in high titre.  The 
positivity of aPL should be confirmed also later, when the acute clinical situation is over. aPL can 
be also positive in sepsis and other critical situations which share several clinical features with 
CAPS.  
The differential diagnosis with sepsis, thrombotic thrombocytopenic purpura (TTP), hemolytic 
uremic syndrome (HUS), acute disseminated intravascular cogulation (DIC) and HELLP 
syndrome (hemolysis, elevated liver enzymes, and low platelets), has to be done. Some of the 
differences between these entities are summarised in Table 2. 
CAPS resembles severe sepsis in its presentation. Both share the symptoms of SIRS [temperature 
>38
o
C, tachycardia, increased respiratory frequency, hypotension, elevated white blood cell count 
or with > 10% immature forms (band)]. Infection is the most common trigger factor of CAPS and, 
sometimes, both situations can co-exist. An aggressive treatment of the infection can markedly 
improve the prognosis.  
TTP, characterised by thrombocytopenia and microangiopathic haemolytic anemia, also share 
with CAPS the presence of renal dysfunction and neurological features. Microangiopathic 
haemolytic anemia consists in a nonimmune hemolysis (direct antiglobulin test negative) together 
with the presence of red cell fragmentation (schistocytes), in peripheral blood smear. The 
presence of more than 1% of schistocyte strongly suggests the diagnosis of TTP (11). 
DIC causes multiple thrombosis and haemorrhage. Its features also include renal, liver, lung and 
central nervous system involvement. The presence of widespread haemorrhage is not so frequent 
in CAPS.  
 
Treatment 
The optimal treatment regime in CAPS is unknown.  Current treatment guidelines suggest, in 
addition to early diagnosis, aggressive therapies to avoid the potentially fatal outcome. The 
combination of high doses of intravenous (i.v.) heparin, i.v. steroids, i.v. immunoglobulins and/or 
repeated plasma exchanges are the basic treatment of choice for all patients with this severe 
condition (Evidence Level II) [10]. 
I.v. heparin is usually administrated during the critical period. When the patient is stable, oral 
anticoagulation with an INR target around 3.0 can be initiated. Heparin is discontinued when the 
target INR is achieved with warfarin. The beneficial effects of Heparin are mediated by its 
capacity to inhibit thrombin, factor Xa and other activated clotting factors [11]. Heparin also 
inhibits complement activation [12]. Nevertheless, this mechanism has not been proven in 
humans, but in the setting of CAPS where there is an important inflammatory component, might 
be relevant. 
Corticosteroids are recommended in a situation with SIRS and excessive cytokine release, as they 
are able to inhibit the proinflammatory status mediated by both the NF-kB and mitogen-activated 
protein kinase pathway [13].  
When initiated promptly plasma exchange (PE) can be considered an effective and safe treatment 
for CAPS. It is useful by removing pathological aPL, cytokines and complement and also 
incorporating natural anticoagulants like antithrombin and protein C. The treatment of CAPS with 
PE is not well standardized. The best replacement fluid for PE is still a controversial issue [14]. 
However, the efficacy of PE has been shown in other thrombotic microangiopathy and since 
CAPS is a critical situation with a high rate of mortality, it is recommended as part of the CAPS 
treatment [15]. 
The rationale to use IVIG in the treatment of CAPS is based on its capacity to block pathological 
antibodies, increases its clearance, acts on the complement system and supresses cytokines [16]. 
Their use in refractory cases of APS resistant to standard therapy has also recently reported [17]. 
IVIG should be specially indicated in situations where there is concomitant infection because of 
its role as immunomodulator rather than immunosuppressor [18]. 
Immunosuppressive drugs such as i.v. cyclophosphamide might be helpful in patients with active 
systemic autoimmune disease mainly SLE and systemic vasculitis but its use in CAPS is not 
associated with an improvement in the survival rate [19]. 
Some case reports about the use of rituximab—an anti-CD20 monoclonal—in the treatment of 
CAPS have been published [20-22] . Although more data are necessary to support the use of this 
drug in the setting of CAPS, current experience seems quite promising, especially in patients with 
severe thrombocytopenia.  More recently, a case of induction of durable remission in recurrent 
CAPS was obtained via inhibition of terminal complement with eculizumab [23]. 
As patients with CAPS have a life-threating condition and high mortality, they need adequate 
management in ICU that should include hemodialysis, mechanical ventilation or cardiovascular 
support for shock. Other factors like aggressive treatment of infection, debridement or amputation 
of necrotic tissues/organs, careful management of intravascular instrumentation, especially 
arterial which can lead to new clots, are extremely important and can substantially improve the 
rate of survival. 
 
Prognosis 
The mortality has been considerably reduced (from more than 50% to 30%) over the past 10 years 
by the use of the recommended therapies. The use of the combination of anticoagulation, 
corticosteroids, plasma exchange and intravenous immunoglobulin (IVIG) has been associated 
with the highest rate of survival [2].  
Data addressing the long-term follow-up of patient with one episode of CAPS are scanty [24]. A 
review including 136 published patients with CAPS showed that 63/136 (46%) died at the time of 
the event. Seventy three patients survived but information was available only from 58 (79%).  
Thirty-eight of 58 (66%) patients did not develop any other thrombotic event during a medium 
follow-up time of 67.2 months. Fifteen of 58 (26%) patients developed further APS related 
thrombosis after the initial catastrophic APS event and the mortality rate of these patients was 
about 25% (4/15 patients). In summary, 66% of survivors remained thrombosis free and 17% 
developed further APS-related thrombosis. None of the patients developed further catastrophic 
APS.  
Comparing the demographic, clinical, and immunologic characteristics of patients who survived 
to those who died, older age, pulmonary and renal involvement, the presence of SLE and high 
titre of antinuclear antibodies (ANA) were associated with a higher mortality rate [25] 
There is few data regarding CAPS relapse. Three patients with seven episodes of CAPS have 
been described. The median time between the episodes was 12.5 months (range, 2.5–48). From 
the clinical point of view, the most significant manifestations were renal involvement (present in 
5 episodes), followed by central nervous system and cardiac involvement (4 episodes each), and 
pulmonary and hepatic involvement (3 episodes each). Interestingly, thrombocytopenia (platelet 
count less than 50 × 10
9
/L) and red cell fragmentation (schistocytes) were reported in all 7 
episodes [26]. In the CAPS registry, a total of 18 episodes of relapse in eight patients, have been 
described [22]. Overall, the precipitating factors in these patients were infection, subtherapeutic 
anticoagulation level and anticoagulation withdrawal. The symptoms were very similar to the first 
CAPS episode (renal failure followed by cerebral, cardiac, and pulmonary involvement). 
Thrombocytopenia was present in 17 patients and hemolytic anemia in 13. LA test was the most 
common aPL positive [19] 
In conclusion, every physician managing patients with multiorgan failure should be aware of the 
possibility of CAPS. This diagnosis should be strongly suspected in patients previously diagnosed 
with APS or any underlying systemic autoimmune disease. A prompt diagnosis will enable 
physicians to take measures to prevent death from this syndrome. An aggressive treatment with 
steroids, anticoagulation and IVIG in an ICU setting, will help prevent the progression of organ 
failure or the development of septic shock in the infected patients. 
Summary 
Catastrophic Antiphospholipid syndrome (CAPS) is a very severe variant of the classic APS, 
characterised by clinical evidence of multiple organ involvement developing over a very short 
period of time,  histopathological evidence of multiple small vessel occlusions, and  laboratory 
confirmation of the presence of antiphospholipid antibodies (aPL), usually in high titre. Although 
patients with catastrophic APS represent less than 1% of all patients with APS, this is usually in a 
life-threatening situation. The mortality has been considerably reduced (from more than 50% to 
30%) over the past 10 years by the use of the recommended therapies (anticoagulation, 
corticosteroids, plasma exchange and IVIG). Relapsing cases still represent a challenge for 
treating physicians.  
 Table 1.  International Classification Criteria for CAPS 
1. Evidence of involvement of 3 organs, systems, and/or tissues 
2. Development of manifestations simultaneously or in less than 1 week 
3. Confirmation by histopathology of small vessel occlusion in at least 1 organ/tissue 
4. Laboratory confirmation of the presence of aPL (LAC and/or aCL and/or anti-2GPI antibodies) 
Definite CAPS:  
 All 4 criteria 
Probable CAPS:  
 All 4 criteria, except for involvement of only 2 organs, system, and/or tissues  
 All 4 criteria, except for the absence of laboratory confirmation at least 6 weeks apart 
associable to the early death of a patient never tested for aPL before onset of CAPS) 
 1, 2, and 4 
 1, 3, and 4, and the development of a third event in > 1 week but <1 month, despite 
anticoagulation treatment 
 
 Table 2. Differential diagnosis of catastrophic antiphospholipid syndrome  
 
 Fibrinogen Hemolytic 
anemia 
Schistocytes Thrombocytopenia aPL 
CAPS Normal +/- +/- +/- ++ 
Sepsis Normal/low + +/- +/- +/- 
TTP-HUS Normal + ++ ++ - 
DIC Low +/- +/- + - 
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